Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för lefradafiban. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

6 träffar

Bibliografisk träff 2010-11-21

Cross-study and cross-omics comparisons of three nephrotoxic compounds reveal mechanistic insights and new candidate biomarkers.

Matheis KA, Com E, Gautier JC, Guerreiro N, Brandenburg A, Gmuender H, Sposny A, Hewitt P, Amberg A, Boernsen O, Riefke B, Hoffmann D, Mally A, Kalkuhl A, Suter L, Dieterle F, Staedtler F.

Toxicol Appl Pharmacol · comparative study; journal article · DOI 10.1016/j.taap.2010.11.006

Bibliografisk träff 2001-04-01

Pharmacodynamics and safety of lefradafiban, an oral platelet glycoprotein IIb/IIIa receptor antagonist, in patients with stable coronary artery disease undergoing elective angioplasty.

Akkerhuis KM, van Den Brand MJ, van Der Zwaan C, Peels HO, Suryapranata H, van Der Wieken LR, Stibbe J, Hoffmann J, Baardman T, Deckers JW, Simoons ML.

Heart · clinical trial, phase ii; clinical trial; research support, non-u.s. gov't; research-article; multicenter study; randomized controlled trial; journal article · DOI 10.1136/heart.85.4.444

Bibliografisk träff 2000-12-01

Safety and preliminary efficacy of one month glycoprotein IIb/IIIa inhibition with lefradafiban in patients with acute coronary syndromes without ST-elevation; a phase II study.

Akkerhuis KM, Neuhaus KL, Wilcox RG, Vahanian A, Boland JL, Hoffmann J, Baardman T, Nehmiz G, Roth U, Klootwijk AP, Deckers JW, Simoons ML, Fibrinogen Receptor Occupancy Study (FROST) Investigators.

Eur Heart J · clinical trial, phase ii; clinical trial; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1053/euhj.2000.2309

Bibliografisk träff 2000-07-01

Absorption of lefradafiban from different sites of the gastrointestinal tract.

Drewe J, Narjes H, Heinzel G, Brickl RS, Rohr A, Beglinger C.

Br J Clin Pharmacol · brief-report; clinical trial; randomized controlled trial; journal article · DOI 10.1046/j.1365-2125.2000.00228.x

Bibliografisk träff 1999-05-01

Lefradafiban. BIBU 104, BIBU 104XX.

Författaruppgift saknas

Drugs R D · journal article · DOI 10.2165/00126839-199901050-00006

Bibliografisk träff 1997-08-01

Profound and sustained inhibition of platelet aggregation by Fradafiban, a nonpeptide platelet glycoprotein IIb/IIIa antagonist, and its orally active prodrug, Lefradafiban, in men.

Müller TH, Weisenberger H, Brickl R, Narjes H, Himmelsbach F, Krause J.

Circulation · controlled clinical trial; clinical trial; clinical trial, phase i; journal article · DOI 10.1161/01.cir.96.4.1130